newsFDA approves first BTK inhibitor for lymphoma30 January 2023 | By Catherine Eckford (European Pharmaceutical Review)The first BTK inhibitor of any kind approved for mantle cell lymphoma treated with a covalent BTK inhibitor, has been granted FDA approval.
newsEli Lilly to help fund cold chain initiative27 January 2023 | By Catherine Eckford (European Pharmaceutical Review)$1.15m funding from Eli Lilly and Company will support a new cold chain capacity initiative in low- and middle-income countries, to help improve medicine access.
newsFDA issues complete response letter for donanemab20 January 2023 | By Catherine Eckford (European Pharmaceutical Review)A complete response letter for Eli Lilly's accelerated approval submission of donanemab for early Alzheimer's has been issued by the US Food and Drug Administration (FDA).
newsLilly and EVA Pharma to aid affordable insulin access in Africa15 December 2022 | By Catherine Eckford (European Pharmaceutical Review)Insulin for at least one million diabetics in low- and middle-income countries, mainly in Africa, is the aim of Eli Lilly and EVA Pharmaceutical's new collaboration.
newsJardiance® improves blood sugar control in type 2 diabetes7 December 2022 | By Catherine Eckford (European Pharmaceutical Review)A Phase III trial showed Jardiance® is the first SGLT2 inhibitor to significantly reduce average blood sugar in type 2 diabetics aged 10-17 compared to placebo.
newsEmpagliflozin reduces risk of chronic kidney disease progression7 November 2022 | By Catherine Eckford (European Pharmaceutical Review)A major trial evaluating Boehringer Ingelheim’s Jardiance®, showed it reduced the risk of cardiovascular death and chronic kidney disease progression by 28 percent.
newsLilly will acquire Akouos to accelerate hearing loss therapies19 October 2022 | By Catherine Eckford (European Pharmaceutical Review)Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.
newsHPAPI market to value $27bn by 20258 June 2022 | By Hannah Balfour (European Pharmaceutical Review)Driven by oncology drug demand, the highly potent active pharmaceutical ingredients (HPAPIs) market is anticipated to grow by $7bn in three years.
newsLilly to build two new US manufacturing sites31 May 2022 | By Hannah Balfour (European Pharmaceutical Review)Eli Lilly and Company announces plans to establish two new manufacturing facilities in Indiana USA worth $2.1 billion.
newsEli Lilly shares impressive hair regrowth results with Olumiant® for alopecia30 March 2022 | By Mandy Parrett (European Pharmaceutical Review)The results of Eli Lilly and Company’s double-blind, placebo-controlled Phase III trials for Olumiant® are encouraging for patients suffering with alopecia.
newsEmpagliflozin trial halted after successful outcome in chronic kidney disease21 March 2022 | By European Pharmaceutical ReviewAn early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
newsEmpagliflozin benefits adults hospitalised for acute heart failure, shows study4 March 2022 | By European Pharmaceutical ReviewPhase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
newsLilly to create $700mn Institute for Genetic Medicine23 February 2022 | By Hannah Balfour (European Pharmaceutical Review)Investing $700mn to establish a new site, Eli Lilly plans to fuel the development of genetic medicines through the company’s new Institute for Genetic Medicine.
newsLilly to build new $1bn manufacturing facility in US31 January 2022 | By Hannah Balfour (European Pharmaceutical Review)The new North Carolinian site will increase parenteral and device manufacturing capacity and create 600 new jobs.
newsProQR and Lilly collaborate to develop RNA therapeutic9 September 2021 | By Anna Begley (European Pharmaceutical Review)ProQR and Lilly announced a collaboration to combat genetic disorders in the liver and nervous system using Axiomer® RNA editing platform.
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-300x278.jpg)
![Eli Lilly logo sign [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Eli-Lilly-e1629971959212.jpg)
